What is HC Wainwright’s Estimate for BTAI Q1 Earnings?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) – Equities researchers at HC Wainwright issued their Q1 2027 earnings per share estimates for BioXcel Therapeutics in a research report issued on Thursday, April 2nd. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings of ($0.31) per share for the quarter. HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for BioXcel Therapeutics’ current full-year earnings is ($24.39) per share. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q2 2027 earnings at ($0.29) EPS, Q3 2027 earnings at ($0.26) EPS and Q4 2027 earnings at ($0.26) EPS.

BioXcel Therapeutics (NASDAQ:BTAI) last released its quarterly earnings data on Friday, March 27th. The company reported ($0.58) EPS for the quarter, meeting the consensus estimate of ($0.58). The firm had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.15 million.

Several other equities analysts have also issued reports on BTAI. Wall Street Zen raised BioXcel Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Weiss Ratings restated a “sell (e+)” rating on shares of BioXcel Therapeutics in a research note on Wednesday, January 21st. Rodman & Renshaw assumed coverage on shares of BioXcel Therapeutics in a report on Tuesday, March 17th. They set a “buy” rating and a $17.00 price objective on the stock. Finally, Zacks Research upgraded shares of BioXcel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, March 9th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $11.00.

BioXcel Therapeutics Price Performance

BTAI opened at $1.18 on Friday. BioXcel Therapeutics has a 1 year low of $1.08 and a 1 year high of $8.08. The company has a market capitalization of $31.95 million, a price-to-earnings ratio of -0.18 and a beta of 0.30. The firm’s fifty day moving average price is $1.56 and its two-hundred day moving average price is $1.93.

Institutional Investors Weigh In On BioXcel Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Millennium Management LLC lifted its holdings in shares of BioXcel Therapeutics by 78.5% during the 4th quarter. Millennium Management LLC now owns 1,835,192 shares of the company’s stock worth $2,936,000 after acquiring an additional 807,139 shares during the last quarter. Oaktree Capital Management LP purchased a new stake in shares of BioXcel Therapeutics in the 2nd quarter valued at $437,000. Geode Capital Management LLC grew its holdings in shares of BioXcel Therapeutics by 64.6% during the 4th quarter. Geode Capital Management LLC now owns 206,168 shares of the company’s stock valued at $330,000 after purchasing an additional 80,928 shares during the last quarter. Jane Street Group LLC purchased a new position in BioXcel Therapeutics in the 4th quarter worth $204,000. Finally, State Street Corp raised its position in BioXcel Therapeutics by 19.9% in the 4th quarter. State Street Corp now owns 63,218 shares of the company’s stock worth $101,000 after purchasing an additional 10,500 shares during the period. 30.68% of the stock is owned by hedge funds and other institutional investors.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.